Same is the case with ATBS, it produces most cost effective high quality ATBS and constantly gaining market share since last 3-4 years.
Regarding IB, its is the raw material for ATBS hence part of it is used by Vinati itself while it has monopoly in India for this, hence majority is consumed in domestic market and rest is exported. Infact they are doing additional capex for IB as well as debottlenecking existing capacity to meet demand.
Yes, on concern-2, first of all the ban is not on IBB but talks is on ban of ipubrofen medicine >> if FDA ban materializes it will definitely impact the sale of IBB (but they have been thinking on this since long) and hence I think management is reducing its exposure and diversifying its product portfolio. For India if it is banned in OTC then you should try asking for it in nearby medical store without prescription to see how well the law is being followed
Disc.: Invested and my views may be biased